Sandra M. Gurrola - 21 Jun 2021 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role
Vice President of Finance
Signature
/s/ Mark L. Johnson, Attorney-in-Fact for Sandra M. Gurrola
Issuer symbol
ERNA
Transactions as of
21 Jun 2021
Net transactions value
$0
Form type
4
Filing time
22 Jun 2021, 18:01:13 UTC
Next filing
17 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA Restricted Stock Unit Award $0 +35,000 $0.000000 35,000 21 Jun 2021 Common Stock 35,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 The option vests and becomes exercisable in four equal installments on June 21 of each of 2022, 2023, 2024 and 2025, provided they shall vest in full immediately prior to a Change in Control (as defined in Ms. Gurrola's Executive Employment Agreement, dated as of June 16, 2021 and effective as of June 21, 2021), subject to continued service through each vesting date.